Immuno-oncology combinations have faced disappointing clinical trial data of late, but positive news from Bristol-Myers Squibb Co.'s Phase III trial testing its PD-1 inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab) in advanced renal cell cancer could swing the pendulum back in their favor.
Bristol announced top-line data from an interim analysis of the Phase III CheckMate 214 study testing the combination in advanced...






